Skip to main content

Table 2 Logistic regression modelling presented as Odds Ratio with 95% confidence interval and corresponding AUC

From: Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department

Target Nursing home residence Hospitalization within 30 days Male sex Renal transplantation Indwelling urinary catheter Use of antibiotics within 30 days Recurrent UTI AUC
Pip/taz n.s. 3.7 (1.4–9.5)** n.s. 15.4 (1.4–172.1)* n.s. n.s. n.s. 0.699
Ciprofloxacin n.s. 4.4 (1.8–10.6)** n.s. n.s. 5.2 (1.8–14.7)** n.s. n.s. 0.749
Gentamicin n.s. n.s. n.s. 24.8 (2.4–257.2)** 3.1 (1.0–9.4)* n.s. n.s. 0.650
Cefuroxime n.s. n.s. 7.3 (2.9–18.5)*** n.s. n.s. 5.7 (1.8–17.7)** n.s. 0.792
Cefpodoxime n.s. n.s. 6.5 (2.5–17.0)*** n.s. n.s. 5.3 (1.7–16.3)** n.s. 0.788
Ceftazidime n.s. n.s. 3.7 (1.3–10.6)* 16.4 (1..5–182.1)* n.s. n.s. n.s. 0.715
MDR n.s. 3.6 (1.5–8.5)** n.s. n.s. n.s. n.s. 4.0 (1.7–9.8)** 0.707
sCPC 22.8 (3.4–151.2)** n.s. 9.5 (1.4–62.5)* n.s. n.s. n.s. n.s. 0.868
  1. * p < 0,05; ** P < 0,01; ***p < 0,001; n.s. not significant, UTI urinary tract infection, AUC Area under the curve, Pip/taz Piperacillin/Tazobactam, MDR multidrug resistance, sCPC simultaneous non-susceptibility for Pip/taz, Ciprofloxacin and Ceftazidime